Febrile Non-hemolytic Transfusion ReactionMANAGEMENT

HEMATOLOGIC AND ONCOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

448 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Acute chest syndrome Acute Hemolytic Transfusion Reaction Anticoagulant reversal (warfarin, DOAC, heparin)Aplastic Anemia (Crisis)Autoimmune Hemolytic Anemia CAR-T and cytokine release syndrome Coagulopathy Delayed Hemolytic Transfusion Reaction Disseminated Intravascular Coagulation (DIC)Essential Thrombocythemia Febrile Non-hemolytic Transfusion Reaction Graft Versus Host Disease (Acute)Hemolytic Uremic Syndrome (HUS)Hemophilia A (Bleeding Crisis)Heparin-Induced Thrombocytopenia (HIT)Hyperviscosity syndrome Immune checkpoint inhibitor toxicity Immune Thrombocytopenic Purpura (ITP)Leukemoid Reaction Leukostasis Massive transfusion protocol Myelofibrosis Neutropenic enterocolitis (typhlitis)Paroxysmal Nocturnal Hemoglobinuria Polycythemia Vera (Crisis)Pure Red Cell Aplasia Sickle Cell (Acute Chest Syndrome)Sickle Cell (Splenic Sequestration)Sickle cell crisis (vaso-occlusive)Symptomatic anemia Thrombocytopenia (severe)Thrombotic Thrombocytopenic Purpura (TTP)Transfusion-Associated Circulatory Overload (TACO)Transfusion-Related Acute Lung Injury (TRALI)Tumor lysis syndrome Von Willebrand Disease (Bleeding)

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp32

Immediate recognition and transfusion stop

›Stop the transfusion immediately at first sign of fever

›Temperature rise >= 1 degree C from baseline during or within 4 hours of transfusion

›Accompanying chills or rigors

›Keep IV line patent with normal saline

›Clerical check — mandatory first step before any workup

›Verify patient wristband against blood product label at bedside

›Confirm unit number and blood type match transfusion record

›Clerical error is the most common cause of fatal hemolytic reactions

Danger signal recognition

›High-risk features requiring urgent hemolysis and sepsis exclusion

›Temperature rise >= 2 degrees C — raises concern for septic transfusion reaction

›Flank or back pain — classic early sign of acute hemolytic transfusion reaction (AHTR)

›Dark or red urine — hemoglobinuria indicating intravascular hemolysis

›Hypotension or tachycardia — consider AHTR, anaphylaxis, or septic reaction

›Respiratory distress or falling SpO2 — consider TRALI or TACO

›Sense of impending doom or severe infusion site pain — highly concerning for AHTR

›Fever and chills are the only early sign of AHTR in 80% of cases

›FNHTR cannot be confirmed until AHTR and sepsis are excluded

›All febrile reactions must be managed as potential AHTR until workup returns

Escalation triggers

›Immediate escalation criteria

›Hemodynamic instability not responding to IV fluids

›SBP < 90 mmHg

›MAP < 65 mmHg

›Respiratory failure or SpO2 falling despite oxygen

›Positive hemolysis workup: pink plasma, positive DAT, rising LDH or bilirubin

›Suspected septic transfusion reaction — blood cultures from patient and product

02History/hx42

Transfusion event details

›Product type and timing

›Type of blood product (RBC, platelets, FFP, cryoprecipitate)

›Platelet transfusions highest reaction rate (821.75 per 100,000 products)

›RBC reactions: 1–3% per unit transfused overall

›Time from start of transfusion to symptom onset

›Symptom onset within minutes to 4 hours is typical

›Severe flushing within 5 minutes followed by fever and rigors at 60 minutes reported

›Rate of infusion at time of reaction

›Number of units transfused in this episode

Symptom characterization

›Core presenting symptoms

›Fever onset and degree

›Temperature >= 38 degrees C

›Rise >= 1 degree C from pre-transfusion baseline

›Chills and rigors

›Rigors present in 14.7% of FNHTR cases

›Severity grading: mild shivering vs uncontrolled rigors

›Nausea or vomiting

›Present in 3.9% of cases

›Back or flank pain

›Present in 1.0% — if present, urgently exclude hemolysis

›Hypotension or dizziness

›Present in 2.4% — if present, urgently exclude AHTR and sepsis

›Respiratory symptoms — dyspnea, cough, chest tightness

›Skin symptoms — urticaria, pruritus, rash suggesting allergic reaction

›Urine color change — dark or red urine suggesting hemoglobinuria

03Physical Exam/exam34

Vital signs

›Hemodynamic stability assessment

›Temperature — document exact value and rise from pre-transfusion baseline

›Rise >= 1 degree C confirms febrile reaction threshold

›Rise >= 2 degrees C requires urgent exclusion of septic reaction

›Blood pressure

›Transient hypertension common in FNHTR

›Hypotension requires urgent exclusion of AHTR, sepsis, anaphylaxis

›Heart rate

›Tachycardia with hypotension — high-risk for serious reaction

›Respiratory rate and SpO2

›Elevated respiratory rate or falling SpO2 — consider TRALI or TACO

General and skin exam

›Overall appearance

›Flushing, diaphoresis, and rigors — consistent with FNHTR

›Pallor or jaundice — raises concern for acute hemolysis

›Distress level and ability to speak full sentences

›Skin findings

›Urticaria, hives, or rash — suggests allergic transfusion reaction rather than FNHTR

›Angioedema — suggests anaphylaxis, particularly in IgA-deficient patients

›IV site — erythema, swelling, or pain suggesting infiltration

Cardiorespiratory exam

›Respiratory exam

›Crackles bilaterally — suggests TRALI or TACO

›Wheeze — anaphylaxis trigger consideration

›Reduced air entry or dullness — pleural effusion

›Cardiovascular exam

›Jugular venous distension — volume overload suggesting TACO

04Differential Diagnosis/ddx38

Life-threatening transfusion reactions to exclude first

›Acute hemolytic transfusion reaction (AHTR)

›ICD-10: T80.30XA — transfusion of incompatible blood

›Fever and chills are the only early signs in 80% of cases

›Additional features: flank pain, hemoglobinuria, positive DAT

›Progression: DIC, renal failure, shock, death

›Differentiating feature: positive DAT, pink post-transfusion plasma, rising LDH

›Septic transfusion reaction

›ICD-10: T80.89XA — other complications of transfusion

›Temperature rise >= 2 degrees C with rigors and hypotension

›Highest risk with platelet transfusions (contamination rate 1 in 5,000 units)

›Differentiating feature: positive Gram stain or culture of product

›Transfusion-related acute lung injury (TRALI)

›ICD-10: J95.84

›Fever plus acute respiratory distress and bilateral infiltrates within 6 hours

›No evidence of volume overload

›Leading cause of transfusion-related death in US

›Anaphylaxis

›ICD-10: T80.59XA

›Hypotension, bronchospasm, urticaria, angioedema

›Consider IgA deficiency with anti-IgA antibodies

›Onset within minutes of starting transfusion

Other transfusion reactions and non-transfusion causes

›Transfusion-associated circulatory overload (TACO)

›ICD-10: J81.0 — acute pulmonary edema

›Dyspnea, hypertension, pulmonary edema, elevated BNP

›Fever present in approximately 29% of pediatric TACO cases

›Differentiating feature: elevated BNP, chest X-ray showing vascular congestion

05Laboratory Tests/lt43

Hemolysis exclusion workup

›Direct antiglobulin test (DAT / direct Coombs)

›Mandatory first-line test to exclude immune-mediated hemolysis

›Negative DAT required before confirming FNHTR

›Sensitivity for AHTR > 95%

›False negative possible with low-grade hemolysis

›Visual inspection of post-transfusion plasma

›Pink or red discoloration indicates hemolysis

›Performed on pre- and post-transfusion sample simultaneously

›Immediate bedside assessment; no laboratory processing required

›Lactate dehydrogenase (LDH)

›Elevated in intravascular hemolysis

›Sensitivity for AHTR approximately 90%

›May also be elevated in TRALI or other causes

›Serum haptoglobin

›Decreased or absent with intravascular hemolysis

›Normal haptoglobin helps exclude significant hemolysis

›Baseline low in liver disease — interpret in context

›Indirect bilirubin

›Elevated within 4–6 hours of significant hemolysis

›Serial measurements increase sensitivity

Blood bank confirmation tests

›Repeat ABO/Rh typing and crossmatch

›To exclude clerical error or mis-labeling of product

›Performed on pre-transfusion sample and current sample

›Most fatal hemolytic reactions caused by ABO incompatibility from clerical error

›Complete blood count

›Unexpected hemoglobin drop greater than anticipated from transfused volume

06Diagnostic Tests/dt35

Scoring Systems

›No validated scoring system specific to FNHTR exists

›FNHTR is a clinical and exclusionary diagnosis

›Severity stratification used clinically

›Mild: temperature rise 1–2 degrees C, chills, responds to antipyretics

›Moderate: rigors, significant discomfort, slow to respond

›Severe/atypical: temperature rise >= 2 degrees C, hypotension, back pain, respiratory symptoms

›When severe/atypical features present, aggressively exclude AHTR, sepsis, TRALI

MRI

›MRI not indicated in the evaluation of FNHTR

›No role for MRI in standard transfusion reaction workup

›May be relevant if neurologic complications of underlying transfusion indication present

›Neurologic complications of massive transfusion assessed with CT head if indicated

›CT not routinely indicated for isolated FNHTR

›CT chest indicated only if TRALI or alternative pulmonary process is suspected

›Ground glass opacities bilateral — TRALI pattern

›Pulmonary vascular congestion — TACO pattern

›CT abdomen not indicated for FNHTR without abdominal complications

›CT head if neurologic deterioration or altered mental status unexplained by fever

Ultrasound

›Bedside ultrasound not routinely required for isolated FNHTR

›Lung ultrasound if respiratory symptoms present

›Bilateral B-lines suggest pulmonary edema consistent with TACO

›Absent B-lines with consolidation — alternative pulmonary pathology

›Inferior vena cava assessment for volume status if hemodynamic instability

›IVC diameter and collapsibility index to guide fluid management

›Cardiac echo if TACO, cardiogenic shock, or unexplained hypotension suspected

07Disposition/dispo23

Discharge criteria

›Safe for discharge when all of the following met

›Symptoms fully resolved — afebrile, no rigors or chills

›Vital signs returned to baseline and stable for >= 1 hour after resolution

›Hemolysis workup negative: negative DAT, clear plasma, no hemoglobinuria

›Sepsis excluded: no hypotension, no bacteremia concerns, cultures pending acceptable if low suspicion

›No respiratory symptoms or SpO2 compromise

›Transfusion reaction reported to blood bank and transfusion medicine

Observation criteria

›Extended observation indicated for

›Slow symptom resolution — persistent fever > 1 hour after antipyretics

›Atypical features requiring lab workup result return

›Moderate severity rigors with delayed response to meperidine

›Uncertainty regarding exclusion of AHTR pending DAT result

Admission criteria

›Admit when any of the following present

›Hemodynamic instability not fully resolved in emergency department

›Confirmed or suspected AHTR — ICU level monitoring

›Confirmed or suspected septic transfusion reaction — broad-spectrum antibiotics and ICU

›TRALI — ICU-level respiratory support likely required

›Ongoing transfusion requirement with complex reaction history

›Failure to improve within 1–2 hours despite appropriate management

Transfusion medicine consultation

›Notify blood bank and transfusion medicine for all transfusion reactions

›Required for hemovigilance reporting and product investigation

›Hematology consultation for recurrent reactions or complex transfusion needs

›Document reaction in medical record and blood bank system for future transfusion planning

08Treatment/t45

Immediate management

›Stop transfusion — first action for any suspected transfusion reaction

›Keep IV line open with normal saline at keep-open rate

›Do not restart the implicated unit under any circumstances

›Initiate transfusion reaction workup protocol simultaneously

Antipyretic therapy

›Acetaminophen for fever and symptom relief

›Acetaminophen 650–1000 mg PO or PR

›Used in approximately 68% of FNHTR cases

›Onset of action 30–45 minutes for oral administration

›Repeat dosing every 4–6 hours as needed

›Maximum 4000 mg per 24 hours in adults; reduce in hepatic impairment

›Non-steroidal anti-inflammatory drugs as alternative if no contraindications

›Ibuprofen 400–600 mg PO with food

›Avoid in renal impairment or active bleeding risk

Rigor management

›Meperidine for severe rigors not responding to antipyretics

›Meperidine 25–50 mg IV slow push

›First-line agent for transfusion-related rigors

›Onset within 5–10 minutes IV

›May repeat once after 20–30 minutes if inadequate response

›Maximum single dose 50 mg IV; use lower end in elderly

›Precautions for meperidine

›Avoid in renal impairment — accumulation of normeperidine metabolite causes seizures

›Avoid with concurrent MAOI use — serotonin syndrome risk

›Use with caution in seizure disorder history

Prevention for future transfusions

›Pre-storage leukoreduction — most effective prevention strategy

09Special Populations/sp46

Pregnancy

›FNHTR in pregnant patients

›Febrile reactions in pregnancy require urgent exclusion of AHTR and sepsis — same threshold

›Fever in pregnancy may independently indicate chorioamnionitis or other obstetric emergency

›Coordinate with obstetrics for fetal monitoring if reaction occurs during antenatal transfusion

›Acetaminophen safe for antipyretic use throughout pregnancy

›Preferred over NSAIDs especially in third trimester (risk of premature ductus closure)

›Meperidine use in late pregnancy — neonatal respiratory depression risk; use with caution

›Multiparous women at increased risk for FNHTR

›Prior pregnancy results in anti-leukocyte antibody formation

›Leukoreduced products preferred in pregnant and multiparous women

›Transfusion indications in pregnancy often urgent

›Postpartum hemorrhage, placenta praevia, hemolytic disease of the newborn

›Reaction management must not delay necessary resuscitation

Geriatric

›FNHTR in elderly patients

›Higher baseline comorbidity risk with transfusion reactions

›Cardiac disease increases TACO risk — monitor for dyspnea and edema

›Renal impairment — avoid meperidine for rigor management

›Hepatic impairment — reduce maximum acetaminophen dose to 2000 mg per 24 hours

›Atypical presentation risk

›Fever may be blunted in elderly immunosuppressed patients

›Delirium may be the presenting feature of a transfusion reaction

›Hypotension more significant in elderly with pre-existing cardiovascular disease

›Drug considerations in elderly

›Meperidine associated with increased delirium risk in elderly — use lowest effective dose

›Renal clearance reduced — normeperidine accumulation risk

›Volume management

10Background/b49

Epidemiology

›Incidence and frequency

›FNHTR is the most common transfusion reaction overall

›Occurs in approximately 1% of transfusion episodes

›Rate of 1–3% per unit transfused depending on product type and leukoreduction status

›Product-specific incidence

›Platelet transfusions: 821.75 reactions per 100,000 products (highest)

›RBC transfusions: substantially lower rate with pre-storage leukoreduction

›FFP and cryoprecipitate: lower rates than cellular products

›Population-specific risk

›Patients with prior transfusion reactions at highest risk of recurrence

›Hematologic malignancy and BMT patients: highest cumulative exposure risk

›Multiparous women: increased anti-leukocyte antibody burden

›Impact of leukoreduction

›Universal pre-storage leukoreduction reduces FNHTR rates by 40–80%

›Non-leukoreduced products carry significantly higher reaction rates

Pathophysiology

›Two-mechanism model of FNHTR

›Cytokine accumulation in stored blood products (primary mechanism for platelet reactions)

›Pro-inflammatory cytokines accumulate during product storage: IL-1beta, IL-6, IL-8, TNF-alpha

›Storage duration > 13 days associated with 3.85x greater odds of FNHTR

›Cytokines released passively — not dependent on recipient immune response

›Explains why FNHTR rates in platelets are reduced by platelet additive solutions (diluting plasma)

›Recipient anti-leukocyte antibody response (primary mechanism for RBC reactions)

›Recipient antibodies against donor human leukocyte antigens (HLA) or human neutrophil antigens (HNA)

›Antigen-antibody reaction activates complement and triggers cytokine release in recipient

›Explains why leukoreduction (removing donor leukocytes) prevents RBC-associated FNHTR

›Thermoregulatory response

11Patient Discharge Instructions/pdi23

copy discharge instructions

›What happened during your transfusion

›You had a febrile non-hemolytic transfusion reaction — the most common type of transfusion reaction

›Your body responded to substances in the blood product with fever and chills

›This reaction is generally not dangerous and is not caused by receiving the wrong blood type

›Testing was done to make sure there was no serious damage to your red blood cells

›What to expect at home

›Your fever and chills should resolve within a few hours

›Mild fatigue or tiredness may persist for 24 hours

›Take acetaminophen (Tylenol) for fever or discomfort as directed by your doctor

›Drink plenty of fluids to stay well hydrated

›Important warning signs — return to emergency department immediately if

›Fever returns or is higher than before

›Dark, brown, or red-colored urine

›Severe back or flank pain

›Difficulty breathing or shortness of breath

›Chest pain

›Feeling faint, dizzy, or like you may pass out

›Skin rash, hives, or swelling of the face or throat

›Future transfusion planning

›Tell any future healthcare provider about this reaction before receiving blood products

›You may be given a special type of blood product (leukoreduced) for future transfusions to reduce reaction risk

›Do not take Tylenol or Benadryl before future transfusions unless specifically instructed by your doctor

›Your reaction has been reported to the blood bank for future reference

12References/r38

Guidelines and key sources

›Delaney M, Wendel S, Bercovitz RS, et al.

›Transfusion Reactions: Prevention, Diagnosis, and Treatment

›Lancet 2016

›PMID 27083327

›Goel R, Tobian AAR, Shaz BH.

›Noninfectious Transfusion-Associated Adverse Events and Their Mitigation Strategies

›Blood 2019

›PMID 30808635

›Panch SR, Montemayor-Garcia C, Klein HG.

›Hemolytic Transfusion Reactions

›New England Journal of Medicine 2019

›NEJM doi 10.1056/NEJMra1802338

›Ning S, Solh Z, Arnold DM, Morin PA.

›Premedication for the Prevention of Nonhemolytic Transfusion Reactions: A Systematic Review and Meta-Analysis

›Transfusion 2019

›PMID 31670424

›Bansal N, Raturi M, Singh C, Bansal Y.

›Immunological Complications of Blood Transfusion: Current Insights and Advances

›Current Opinion in Immunology 2025

›PMID 40737911

›Stone EF, Chacreton D, Jimenez A, et al.

›Epidemiology of Pediatric Transfusion Reactions

›JAMA Network Open 2026

Landmark trials and systematic reviews

›Kennedy LD, Case LD, Hurd DD, Cruz JM, Pomper GJ.

›Prospective, Randomized, Double-Blind Controlled Trial of Acetaminophen and Diphenhydramine Pretransfusion Medication Versus Placebo

›Transfusion 2008

Learn More: Febrile Non-hemolytic Transfusion Reaction→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.